Vectura to receive $9.5m payment and up to $25m loan facility

18 March 2010: Vectura Group plc (LSE: VEC), the specialty pharmaceutical company, announces that it has agreed with Sandoz AG to take full control of the US development and commercialisation of VR315, its combination product for asthma/COPD. Good progress continues to be made with the development of VR315. In Europe, there is no change to the agreement signed in April 2006, and Sandoz will continue to be fully responsible for the development, manufacture and commercialisation of the product.


Under the revised agreement, Vectura regains full rights and responsibilities for the development and commercialisation of VR315 in the US and is released from its profit share obligations. The reacquisition of full control of this important product in the US is part of Vectura’s strategy to become a cash-generative specialty pharmaceutical company, and VR315 will form the cornerstone of Vectura’s nascent US operations... Vectura's Press Release -

Vectura and Sosei, Phase II Studies of QVA149 for the Treatment of COPD

15 November 2007 - Vectura Group plc (“Vectura”; LSE: VEC) and Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) announce the start, by Novartis, of a Phase II safety study of QVA149 for the treatment of chronic obstructive pulmonary disease (COPD). QVA149 is a combination of NVA237, a once-daily long-acting muscarinic antagonist (LAMA) and indacaterol, a once-daily long-acting beta-2 agonist (LABA)... Vectura's Press Release - Sosei's Press Release [PDF] -